Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 9/20 | 0.42 |
| ▸ | JAK1 | P23458 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561044 | 0.88 | GRM5 (0.50) | POLBJAK2JAK1TSHRGRM5 | |
| SCHEMBL29814621 | 0.87 | JAK2 (0.42) | POLBJAK2JAK1TSHRGRM5 | |
| SCHEMBL22391949 | 0.87 | JAK2 (0.42) | POLBJAK2JAK1TSHRGRM5 | |
| SCHEMBL3561664 | 0.87 | GPR119 (0.41) | JAK2JAK1GRM5GPR119CYP11B2 | |
| SCHEMBL24265731 | 0.84 | POLB (0.46) | POLBTSHRGRM5ALOX15OPRD1 | |
| SCHEMBL29574116 | 0.84 | POLB (0.46) | POLBTSHRGRM5ALOX15OPRD1 | |
| SCHEMBL16220176 | 0.82 | JAK2 (0.45) | POLBJAK2JAK1MEN1KMT2A | |
| SCHEMBL759250 | 0.82 | CA12 (0.39) | GRM5 | |
| SCHEMBL20266525 | 0.82 | TSHR (0.48) | POLBTSHRGRM5ALOX15OPRD1 | |
| SCHEMBL29555767 | 0.82 | TSHR (0.48) | POLBTSHRGRM5ALOX15OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709451-B1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2709451-B1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| EP-2709451-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158475-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158475-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-1942733-B1 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7834031-B2 | Radiolabeled glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| EP-1942733-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041025-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | POLB 3173/4885JAK2 4820/4885JAK1 4677/4885 |
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | SLC6A5, SLC1A5, SLC1A3 | POLB 4292/4885JAK2 4760/4885JAK1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.